Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2017 (2017), Article ID 8391637, 8 pages
https://doi.org/10.1155/2017/8391637
Research Article

Modified Suanzaorentang Had the Treatment Effect for Generalized Anxiety Disorder for the First 4 Weeks of Paroxetine Medication: A Pragmatic Randomized Controlled Study

1Internal Medicine of Traditional Chinese Medicine, The 2nd Clinical Medical College, Zhejiang Chinese Medical University, 548 Binwen Road, Hangzhou, Zhejiang 310053, China
2Molecular Biology Laboratory, Hangzhou Seventh People’s Hospital, 305 Tianmushan Road, Hangzhou, Zhejiang 310013, China
3Psychosomatic Disorders Department, Hangzhou Seventh People’s Hospital, 305 Tianmushan Road, Hangzhou, Zhejiang 310013, China

Correspondence should be addressed to Yong-Hua Zhang

Received 2 February 2017; Revised 17 March 2017; Accepted 6 April 2017; Published 3 May 2017

Academic Editor: Haroon Khan

Copyright © 2017 Ming-Fen Song et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. X. Zhang, J. Norton, I. Carrière, K. Ritchie, I. Chaudieu, and M. Ancelin, “Risk factors for late-onset generalized anxiety disorder: results from a 12-year prospective cohort (The ESPRIT study),” Translational Psychiatry, vol. 5, p. e536, 2015. View at Publisher · View at Google Scholar
  2. M. Cvjetkovic-Bosnjak, B. Soldatovic-Stajic, S. S. Babovic, K. Boskovic, and M. Jovicevic, “Pregabalin versus sertraline in generalized anxiety disorder. An open label study,” European Review for Medical and Pharmacological Sciences, vol. 19, no. 11, pp. 2120–2124, 2015. View at Google Scholar · View at Scopus
  3. H. Y. Khdour, O. M. Abushalbaq, I. T. Mughrabi et al., “Generalized anxiety disorder and social anxiety disorder, but not panic anxiety disorder, are associated with higher sensitivity to learning from negative feedback: behavioral and computational investigation,” Front Integr Neurosci, vol. 10, p. 20, 2016. View at Google Scholar
  4. Y. Wang, F. Chai, H. Zhang et al., “Cortical functional activity in patients with generalized anxiety disorder,” BMC Psychiatry, vol. 16, p. 217, 2016. View at Publisher · View at Google Scholar
  5. Z. Farzampour, R. J. Reimer, and J. Huguenard, “Endozepines,” Advances in Pharmacology, vol. 72, pp. 147–164, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. B. D. Fischer, L. P. Teixeira, M. L. Van Linn et al., “Role of gamma-aminobutyric acid type A (GABAA) receptor subtypes in acute benzodiazepine physical dependence-like effects: evidence from squirrel monkeys responding under a schedule of food presentation,” Psychopharmacology, vol. 227, no. 2, pp. 347–354, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Pariente, S. B. De Gage, N. Moore, and B. Bégaud, “The benzodiazepine-dementia disorders link: current state of knowledge,” CNS Drugs, vol. 30, no. 1, pp. 1–7, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Allgulander, B. Bandelow, E. Hollander et al., “WCA recommendations for the long-term treatment of generalized anxiety disorder,” CNS Spectrums, vol. 8, no. 8, pp. 53–61, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. D. S. Baldwin, S. Waldman, and C. Allgulander, “Evidence-based pharmacological treatment of generalized anxiety disorder,” International Journal of Neuropsychopharmacology, vol. 14, no. 5, pp. 697–710, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Perna, A. Alciati, A. Riva, W. Micieli, and D. Caldirola, “Long-term pharmacological treatments of anxiety disorders: an updated systematic review,” Current Psychiatry Reports, vol. 18, no. 3, article 23, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. S. G. Ball, A. Kuhn, D. Wall, A. Shekhar, and A. W. Goddard, “Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline,” The Journal of Clinical Psychiatry, vol. 66, pp. 94–99, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Gao, D. V. Sheehan, and J. R. Calabrese, “Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders,” Expert Review of Neurotherapeutics, vol. 9, no. 8, pp. 1147–1158, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. H. MacPherson, “Pragmatic clinical trials,” Complementary Therapies in Medicine, vol. 12, no. 2-3, pp. 136–140, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Y. Chan, Y. H. Chen, S. N. Yang, W. Y. Lo, and J. G. Lin, “Clinical efficacy of traditional Chinese medicine, Suan Zao Ren Tang, for sleep disturbance during methadone maintenance: a randomized, double-blind, placebo-controlled trial,” Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 710895, 9 pages, 2015. View at Publisher · View at Google Scholar
  15. Q.-Q. Liu, J. Zhang, R.-J. Guo et al., “Efficacy and safety of the Chaihuguizhiganjiang-suanzaoren granule on primary insomnia: study protocol for a randomised controlled trial,” BMJ Open, vol. 6, no. 2, Article ID e008459, 2016. View at Publisher · View at Google Scholar · View at Scopus
  16. V. O. Chakhava, F. S. Budtueva, and R. R. Borukaev, “Efficacy of adepress (paroxetine) in generalized anxiety disorder,” Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova, vol. 110, pp. 25–29, 2010. View at Google Scholar
  17. M. Bourin, P. Chue, and Y. Guillon, “Paroxetine: a review,” CNS Drug Reviews, vol. 7, no. 1, pp. 25–47, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. J.-P. Guilloux, D. J. P. David, L. Xia et al., “Characterization of 5-HT1A/1B-/- mice: an animal model sensitive to anxiolytic treatments,” Neuropharmacology, vol. 61, no. 3, pp. 478–488, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. V. R. Sela, C. Biesdorf, D. H. Ramos, H. Zangrossi, F. G. Graeff, and E. A. Audi, “Serotonin-1A receptors in the dorsal periaqueductal gray matter mediate the panicolytic-like effect of pindolol and paroxetine combination in the elevated T-maze,” Neuroscience Letters, vol. 495, no. 1, pp. 63–66, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. E. A. Pineda, J. G. Hensler, R. Sankar, D. Shin, T. F. Burke, and A. M. Mazarati, “Plasticity of presynaptic and postsynaptic serotonin 1A receptors in an animal model of epilepsy-associated depression,” Neuropsychopharmacology, vol. 36, no. 6, pp. 1305–1316, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. R. H. McAllister-Williams, H. A. Alhaj, A. Massey, J. Pankiv, and U. Reckermann, “Somatodendritic 5-hydroxytryptamine1A (5-HT1A) autoreceptor function in major depression as assessed using the shift in electroencephalographic frequency spectrum with buspirone,” Psychological Medicine, vol. 44, no. 4, pp. 767–777, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Savitz, I. Lucki, and W. C. Drevets, “5-HT1A receptor function in major depressive disorder,” Progress in Neurobiology, vol. 88, no. 1, pp. 17–31, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Blier and N. M. Ward, “Is there a role for 5-HT1A agonists in the treatment of depression?” Biological Psychiatry, vol. 53, no. 3, pp. 193–203, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Tao, M. Rudacille, G. Zhang, and Z. Ma, “Changes in intensity of serotonin syndrome caused by adverse interaction between monoamine oxidase inhibitors and serotonin reuptake blockers,” Neuropsychopharmacology, vol. 39, no. 8, pp. 1996–2007, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. L.-L. Hu, X. Zhang, W.-J. Liu, M. Li, and Y.-H. Zhang, “Suan zao ren tang in combination with zhi zi chi tang as a treatment protocol for insomniacs with anxiety: a randomized parallel-controlled trial,” Evidence-based Complementary and Alternative Medicine, vol. 2015, Article ID 913252, 7 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. F. Ferre Navarrete, M. Pérez Páramo, J. Fermin Ordoño, and V. López Gómez, “Prevalence of insomnia and associated factors in outpatients with generalized anxiety disorder treated in psychiatric clinics,” Behavioral Sleep Medicine, pp. 1–11, 2016. View at Publisher · View at Google Scholar · View at Scopus
  27. M. P. Herring, C. E. Kline, and P. J. O'Connor, “Effects of exercise on sleep among young women with Generalized Anxiety Disorder,” Mental Health and Physical Activity, vol. 9, pp. 59–66, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. B. Yang, A. Zhang, H. Sun et al., “Metabolomic study of insomnia and intervention effects of Suanzaoren decoction using ultra-performance liquid-chromatography/electrospray-ionization synapt high-definition mass spectrometry,” Journal of Pharmaceutical and Biomedical Analysis, vol. 58, no. 1, pp. 113–124, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. P.-L. Yi, C.-P. Lin, C.-H. Tsai, J.-G. Lin, and F.-C. Chang, “The involvement of serotonin receptors in suanzaorentang-induced sleep alteration,” Journal of Biomedical Science, vol. 14, no. 6, pp. 829–840, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. P.-L. Yi, C.-H. Tsai, Y.-C. Chen, and F.-C. Chang, “Gamma-aminobutyric acid (GABA) receptor mediates suanzaorentang, a traditional Chinese herb remedy, -induced sleep alteration,” Journal of Biomedical Science, vol. 14, no. 2, pp. 285–297, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. J. N. Lai, J. L. Tang, and J. D. Wang, “Observational studies on evaluating the safety and adverse effects of traditional Chinese medicine,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 697893, 9 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. R. S. Oosting, J. S. Chan, B. Olivier, P. Banerjee, Y. K. Choi, and F. Tarazi, “Differential effects of vilazodone versus citalopram and paroxetine on sexual behaviors and serotonin transporter and receptors in male rats,” Psychopharmacology, vol. 233, no. 6, pp. 1025–1034, 2016. View at Publisher · View at Google Scholar · View at Scopus
  33. R. S. Oosting, J. S. W. Chan, B. Olivier, and P. Banerjee, “Vilazodone does not inhibit sexual behavior in male rats in contrast to paroxetine: a role for 5-HT1A receptors?” Neuropharmacology, vol. 107, pp. 271–277, 2016. View at Publisher · View at Google Scholar · View at Scopus